Joseph Paul Antonios, MD/PhD
Hospital Resident
Research & Publications
Biography
News
Coauthors
Selected Publications
- Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II TrialEverson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 4800. PMID: 38839763, PMCID: PMC11153605, DOI: 10.1038/s41467-024-48995-7.
- TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II TrialEverson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 3882. PMID: 38719809, PMCID: PMC11078958, DOI: 10.1038/s41467-024-48073-y.
- Use of a dedicated open transcarotid access system for neurovascular diseaseSujijantarat N, Renedo D, Antonios J, Koo A, Amllay A, Nowicki K, Cord B, Hebert R, de Havenon A, Sheth K, Petersen N, Matouk C. Use of a dedicated open transcarotid access system for neurovascular disease. Journal Of NeuroInterventional Surgery 2024, jnis-2024-021599. PMID: 38719442, DOI: 10.1136/jnis-2024-021599.
- Angiographic evidence of an inadvertent cannulation of the marginal sinus following central line migration: illustrative caseAmllay A, Owolo E, Nowicki K, Sujijantarat N, Koo A, Antonios J, Renedo D, Matouk C, Hebert R. Angiographic evidence of an inadvertent cannulation of the marginal sinus following central line migration: illustrative case. Journal Of Neurosurgery Case Lessons 2024, 7: case23607. PMID: 38684119, PMCID: PMC11058405, DOI: 10.3171/case23607.
- The eShunt® System: A Novel Minimally Invasive CSF Shunting System for the Treatment of Idiopathic Normal Pressure Hydrocephalus (P10-4.014)Lylyk P, Matouk C, Siddiqui A, Riina H, Lylyk I, Bleise C, Scrivano E, Lylyk P, Antonios J, Beneduce B, Levy E, Heilman C, Malek A. The eShunt® System: A Novel Minimally Invasive CSF Shunting System for the Treatment of Idiopathic Normal Pressure Hydrocephalus (P10-4.014). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206181.
- 157 Minimally Invasive Treatment of Idiopathic Normal Pressure Hydrocephalus Using the Endovascular eShunt ImplantLylyk P, Matouk C, Siddiqui A, Lylyk I, Bleise C, Scrivano E, Lylyk N, Antonios J, Beneduce B, Levy E, Heilman C, Malek A. 157 Minimally Invasive Treatment of Idiopathic Normal Pressure Hydrocephalus Using the Endovascular eShunt Implant. Neurosurgery 2024, 70: 36-37. DOI: 10.1227/neu.0000000000002809_157.
- 308 Improvement in Cranial Nerve Neuropathies Following Treatment of Intracranial Aneurysms With Flow Diverters: Institutional Outcomes and Meta-analysis of LiteratureSujijantarat N, Antonios J, Koo A, Haynes J, Renedo D, Hebert R, Sheth K, King J, Matouk C. 308 Improvement in Cranial Nerve Neuropathies Following Treatment of Intracranial Aneurysms With Flow Diverters: Institutional Outcomes and Meta-analysis of Literature. Neurosurgery 2024, 70: 89-89. DOI: 10.1227/neu.0000000000002809_308.
- 306 Endothelial Infiltrating Regulatory B Cells and NK T Cells Precipitate Inflammatory Cascade That Leads to Aneurysmal RuptureAntonios J, Barak T, Gultekin B, Yalcin K, Adenu-Mensah N, Sujijantarat N, Koo A, Haynes J, Hebert R, Matouk C, Gunel M. 306 Endothelial Infiltrating Regulatory B Cells and NK T Cells Precipitate Inflammatory Cascade That Leads to Aneurysmal Rupture. Neurosurgery 2024, 70: 88-89. DOI: 10.1227/neu.0000000000002809_306.
- Low‐Field Portable Magnetic Resonance Imaging for Post‐Thrombectomy Assessment of Ongoing Brain InjurySujijantarat N, Koo A, Jambor I, Malhotra A, Mazurek M, Parasuram N, Yadlapalli V, Chavva I, Lalwani D, Zabinska J, Roy J, Antonios J, Elsamadicy A, Renedo D, Hebert R, Schindler J, Gilmore E, Sansing L, de Havenon A, Olexa M, Schiff S, Iglesias J, Rosen M, Kimberly W, Petersen N, Sheth K, Matouk C. Low‐Field Portable Magnetic Resonance Imaging for Post‐Thrombectomy Assessment of Ongoing Brain Injury. Stroke Vascular And Interventional Neurology 2023, 3 DOI: 10.1161/svin.123.000921.
- Abstract P1018: Peptidyl-prolyl Cis-trans Isomerase-like 4 Is A Novel Regulator Of Smooth Muscle Cell RemodelingGultekin B, Yalcin K, Antonios J, Miyagishima D, Erson Omay Z, Barak T, Gunel M. Abstract P1018: Peptidyl-prolyl Cis-trans Isomerase-like 4 Is A Novel Regulator Of Smooth Muscle Cell Remodeling. Circulation Research 2023, 133 DOI: 10.1161/res.133.suppl_1.p1018.
- O-039 Preliminary results of the cerevasc eShunt implant in the treatment of normal pressure hydrocephalusLylyk P, Matouk C, Siddiqui A, Lylyk I, Bleise C, Scrivano E, Lylyk N, Antonios J, Beneduce B, Levy E, Heilman C, Malek A. O-039 Preliminary results of the cerevasc eShunt implant in the treatment of normal pressure hydrocephalus. 2023, a31-a32. DOI: 10.1136/jnis-2023-snis.39.
- O-068 Regulatory B cell and adjunctive immune population drives intracranial aneurysm rupture in patient populationAntonios J, Barak T, Gultekin B, Yalcin K, Chamberlain A, Hebert R, Matouk C, Gunel M. O-068 Regulatory B cell and adjunctive immune population drives intracranial aneurysm rupture in patient population. 2023, a53.1-a53. DOI: 10.1136/jnis-2023-snis.68.
- 472 Low-Field Portable Magnetic Resonance Imaging for Bedside Evaluation of Ischemic Stroke in Post-Thrombectomy PatientsSujijantarat N, Koo A, Jambour I, Malhotra A, Crawford A, Mazurek M, Parasuram N, Chavva I, Sze G, Renado D, Antonios J, Elsamadicy A, Hebert R, Petersen N, Sheth K, Matouk C. 472 Low-Field Portable Magnetic Resonance Imaging for Bedside Evaluation of Ischemic Stroke in Post-Thrombectomy Patients. Neurosurgery 2023, 69: 100-100. DOI: 10.1227/neu.0000000000002375_472.
- 550 Hospital Frailty Risk Score is an Independent Risk Factor for VP Shunt Placement for Ruptured Intracranial AneurysmsKoo A, Elsamadicy A, Sarkozy M, Reeves B, Craft S, Sherman J, Sayeed S, Antonios J, Renedo D, Sujijantarat N, Hebert R, Malhotra A, Matouk C. 550 Hospital Frailty Risk Score is an Independent Risk Factor for VP Shunt Placement for Ruptured Intracranial Aneurysms. Neurosurgery 2023, 69: 120-120. DOI: 10.1227/neu.0000000000002375_550.
- Abstract WP154: Low-field Portable Mri For Routine Post-thrombectomy Assessment Of Ongoing Brain InjurySujijantarat N, Koo A, Jambor I, Malhotra A, Crawford A, Mazurek M, Parasuram N, Yadlapalli V, Chavva I, Antonios J, Elsamadicy A, Renedo D, Hebert R, Schindler J, Sansing L, De Havenon A, Olexa M, Iglesias J, Rosen M, Kimberly W, Petersen N, Sheth K, Matouk C. Abstract WP154: Low-field Portable Mri For Routine Post-thrombectomy Assessment Of Ongoing Brain Injury. Stroke 2023, 54: awp154-awp154. DOI: 10.1161/str.54.suppl_1.wp154.
- Abstract 15: Single-cell Immune Landscape Of Human Clot Retrieved At Mechanical Thrombectomy. Association With Stroke Origin.Renedo D, Sujijantarat N, Antonios J, Koo A, Acosta J, Falcone G, Hebert R, Sansing L, Navaratnam D, Matouk C. Abstract 15: Single-cell Immune Landscape Of Human Clot Retrieved At Mechanical Thrombectomy. Association With Stroke Origin. Stroke 2023, 54: a15-a15. DOI: 10.1161/str.54.suppl_1.15.
- Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer.Kowalchuk R, Niranjan A, Hess J, Antonios J, Zhang M, Braunstein S, Ross R, Pikis S, Deibert C, Lee C, Yang H, Langlois A, Mathieu D, Peker S, Samanci Y, Rusthoven C, Chiang V, Wei Z, Lunsford L, Trifiletti D, Sheehan J. Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer. Journal Of Neurosurgery 2022, 138: 1608-1614. PMID: 36433878, DOI: 10.3171/2022.10.jns221900.
- Navigating an Internal Carotid Artery Anatomic Variant During Endovascular Therapy for Acute Ischemic StrokePeng T, Sharma R, Antonios J, Hebert R, Jasne A. Navigating an Internal Carotid Artery Anatomic Variant During Endovascular Therapy for Acute Ischemic Stroke. Stroke 2022, 53: e517-e518. PMID: 36106549, DOI: 10.1161/strokeaha.122.040501.
- 307 The Hospital Frailty Risk Score Independently Predicts Increased Complication Rates and Healthcare Resource Utilization After Endovascular Treatment of Ruptured AneurysmsKoo A, Elsamadicy A, Sarkozy M, Sherman J, Reeves B, Freedman I, Antonios J, Sujijantarat N, Renado D, Hebert R, Malhotra A, Matouk C. 307 The Hospital Frailty Risk Score Independently Predicts Increased Complication Rates and Healthcare Resource Utilization After Endovascular Treatment of Ruptured Aneurysms. Neurosurgery 2022, 68: 67-68. DOI: 10.1227/neu.0000000000001880_307.
- INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMABarak T, Hwang L, Chen J, Jin L, Miyagishima D, Yalcin K, Ogilvie S, Antonios J, Theriault B, Huttner A, McGuone D, Lifton N, Blondin N, Corbin Z, Zhang Y, Gunel M, Erson-Omay Z, Fulbright R, Tabar T, Moliterno-Gunel J. INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi107-vi107. PMCID: PMC8598632, DOI: 10.1093/neuonc/noab196.421.
- In Silico Analysis of Changes in Immunological Landscape During Malignant Transformation of IDH-mutant Low-grade GliomasYeung J, Vesely M, Antonios J, Miyagishima D. In Silico Analysis of Changes in Immunological Landscape During Malignant Transformation of IDH-mutant Low-grade Gliomas. Neurosurgery 2020, 67 DOI: 10.1093/neuros/nyaa447_835.
- Race and All-cause Mortality in Patients with a Primary Malignant or Nonmalignant Tumor of the Spinal Cord or Spinal MeningesElsamadicy A, Freedman I, Koo A, David W, Reeves B, Antonios J, Laurans M, Kolb L, Sciubba D. Race and All-cause Mortality in Patients with a Primary Malignant or Nonmalignant Tumor of the Spinal Cord or Spinal Meninges. Neurosurgery 2020, 67 DOI: 10.1093/neuros/nyaa447_203.
- CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTSChavez C, Everson R, Orpilla J, Lee A, Khattab S, Antonios J, Salazar A, Cloughesy T, Liau L, Sun L, Hugo W, Prins R. CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2020, 22: ii36-ii37. PMCID: PMC7650313, DOI: 10.1093/neuonc/noaa215.152.
- Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccinationAntonios J, Everson R, Mochizuki A, Khattab S, Soto H, Romiyo P, Sun M, Moughon D, Billingslea-Yoon E, Odesa S, Li G, Kawaguchi E, Salazar A, Yong W, Schlossman J, Ellingson B, Wang A, Cloughesy T, Prins R, Liau L. Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination. Cancer Immunology Research 2020, 8: pr13-pr13. DOI: 10.1158/2326-6074.tumimm19-pr13.
- IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMASun M, Orpilla J, Contreras E, Treger J, Molaie D, Tsang J, Antonios J, Wang A, Liau L, Prins R, Everson R. IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA. Neuro-Oncology 2019, 21: vi129-vi130. PMCID: PMC6847786, DOI: 10.1093/neuonc/noz175.542.
- Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and ActivationDavidson T, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki A, Antonios J, Garcia A, Kotecha N, Bayless N, Nathanson D, Wang A, Everson R, Yong W, Cloughesy T, Liau L, Herold-Mende C, Prins R. Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clinical Cancer Research 2019, 25: 1913-1922. PMID: 30498094, PMCID: PMC6420851, DOI: 10.1158/1078-0432.ccr-18-1176.
- SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activationLiu F, Cox C, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, Prins R, Nghiemphu P, Yong W, Cloughesy T, Lai A. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal Of Neuro-Oncology 2019, 142: 423-434. PMID: 30838489, PMCID: PMC6516751, DOI: 10.1007/s11060-019-03126-x.
- Immunosuppressive mechanisms for stem cell transplant survival in spinal cord injury.Antonios J, Farah G, Cleary D, Martin J, Ciacci J, Pham M. Immunosuppressive mechanisms for stem cell transplant survival in spinal cord injury. Neurosurgical FOCUS 2019, 46: e9. PMID: 30835678, DOI: 10.3171/2018.12.focus18589.
- ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATIONAntonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology 2018, 20: vi10-vi10. PMCID: PMC6216157, DOI: 10.1093/neuonc/noy148.034.
- 214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging TechniquesAntonios J, Soto H, Everson R, Wang A, Bethel J, Radu C, Ellingson B, Phelps M, Cloughesy T, Prins R, Liau L. 214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging Techniques. Neurosurgery 2018, 65: 120. DOI: 10.1093/neuros/nyy303.214.
- Cell-Based Immunotherapy of GliomasEverson R, Antonios J, Liau L. Cell-Based Immunotherapy of Gliomas. 2018, 32: 90-100. PMID: 29990977, DOI: 10.1159/000469683.
- NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRISoto H, Antonios J, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI. Neuro-Oncology 2017, 19: vi149-vi150. PMCID: PMC5692246, DOI: 10.1093/neuonc/nox168.611.
- Detection of immune responses after immunotherapy in glioblastoma using PET and MRIAntonios J, Soto H, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 10220-10225. PMID: 28874539, PMCID: PMC5617282, DOI: 10.1073/pnas.1706689114.
- Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiformeQin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios J, Kasahara N, Yang I, Prins R, Braun J, Gordon L, Wadehra M. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. Journal Of Neuro-Oncology 2017, 134: 29-40. PMID: 28597184, PMCID: PMC5695892, DOI: 10.1007/s11060-017-2507-8.
- Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastomaAntonios J, Soto H, Everson R, Moughon D, Orpilla J, Shin N, Sedighim S, Treger J, Odesa S, Tucker A, Yong W, Li G, Cloughesy T, Liau L, Prins R. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology 2017, 19: 796-807. PMID: 28115578, PMCID: PMC5464463, DOI: 10.1093/neuonc/now287.
- Chapter 12 Dendritic Cell Therapy for Brain TumorsEverson R, Antonios J, Tucker A, Liau L. Chapter 12 Dendritic Cell Therapy for Brain Tumors. 2017, 301-321. DOI: 10.1016/b978-0-12-802420-1.00012-0.
- TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMAAntonios J, Soto H, Everson R, Orpilla J, Shin N, Moughon D, Sedighim S, Treger J, Odesa S, Tucker A, Yong W, Cloughesy T, Prins R, Liau L. TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology 2016, 18: vi203-vi203. DOI: 10.1093/neuonc/now212.856.
- IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSESEverson R, Shin N, Antonios J, Soto H, Tucker A, Zaretsky J, Orpilla J, Rathe S, Popescu F, Largaespada D, Liau L, Prins R. IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES. Neuro-Oncology 2016, 18: vi99-vi99. DOI: 10.1093/neuonc/now212.412.
- IMST-28. NON-INVASIVE IMMUNE MONITORING FOLLOWING DC VACCINATION EFFECTIVELY DELINEATES IMMUNE RESPONSES IN GLIOBLASTOMAAntonios J, Soto H, Everson R, Orpilla J, Shin N, Nathanson D, Harris R, Sadeghi S, Ellingson B, Liau L, Prins R. IMST-28. NON-INVASIVE IMMUNE MONITORING FOLLOWING DC VACCINATION EFFECTIVELY DELINEATES IMMUNE RESPONSES IN GLIOBLASTOMA. Neuro-Oncology 2016, 18: vi92-vi92. DOI: 10.1093/neuonc/now212.384.
- Abstract 767: TCR sequencing can identify and track tumor-specific T cell populations and is a predictive biomarker of response to DC vaccination in glioblastoma patientsSedighim S, Hsu M, Wang T, Everson R, Tucker A, Antonios J, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson T, Li G, Liau L, Prins R. Abstract 767: TCR sequencing can identify and track tumor-specific T cell populations and is a predictive biomarker of response to DC vaccination in glioblastoma patients. Cancer Research 2016, 76: 767-767. DOI: 10.1158/1538-7445.am2016-767.
- PD-1 blockade enhances the vaccination-induced immune response in gliomaAntonios J, Soto H, Everson R, Orpilla J, Moughon D, Shin N, Sedighim S, Yong W, Li G, Cloughesy T, Liau L, Prins R. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 2016, 1: e87059. PMID: 27453950, PMCID: PMC4951098, DOI: 10.1172/jci.insight.87059.
- TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC VaccinationHsu M, Sedighim S, Wang T, Antonios J, Everson R, Tucker A, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson T, Li G, Liau L, Prins R. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research 2016, 4: 412-418. PMID: 26968205, PMCID: PMC4873445, DOI: 10.1158/2326-6066.cir-15-0240.
- TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENTAntonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT. Neuro-Oncology 2015, 17: v214-v215. PMCID: PMC4639289, DOI: 10.1093/neuonc/nov236.04.
- IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTSSedighim S, Hsu M, Antonios J, Emerson R, Yusko E, Sanders C, Davidson T, Liau L, Prins R. IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS. Neuro-Oncology 2015, 17: v109-v110. PMCID: PMC4638907, DOI: 10.1093/neuonc/nov218.11.
- Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor responseAntonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response. Journal For ImmunoTherapy Of Cancer 2015, 3: p393. PMCID: PMC4652564, DOI: 10.1186/2051-1426-3-s2-p393.
- Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastomaEverson R, Antonios J, Lisiero D, Soto H, Scharnweber R, Garrett M, Yong W, Li N, Li G, Kruse C, Liau L, Prins R. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology 2015, 18: 368-378. PMID: 26330563, PMCID: PMC4767237, DOI: 10.1093/neuonc/nov153.
- pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRIHarris R, Cloughesy T, Liau L, Prins R, Antonios J, Li D, Yong W, Pope W, Lai A, Nghiemphu P, Ellingson B. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology 2015, 17: 1514-1524. PMID: 26113557, PMCID: PMC4648305, DOI: 10.1093/neuonc/nov106.
- Dendritic cell immunotherapy for brain tumorsAntonios J, Everson R, Liau L. Dendritic cell immunotherapy for brain tumors. Journal Of Neuro-Oncology 2015, 123: 425-432. PMID: 26037466, DOI: 10.1007/s11060-015-1830-1.
- IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMAAntonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA. Neuro-Oncology 2014, 16: v110-v110. PMCID: PMC4218227, DOI: 10.1093/neuonc/nou258.1.
- Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironmentHa E, Antonios J, Soto H, Prins R, Yang I, Kasahara N, Liau L, Kruse C. Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunology And Neuroinflammation 2014, 1: 66-76. DOI: 10.4103/2347-8659.139717.